Literature DB >> 36248754

Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.

Lamya Alnaim1.   

Abstract

This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET. ©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.

Entities:  

Keywords:  Breast cancer; hormonal therapy; quality of life; women

Year:  2022        PMID: 36248754      PMCID: PMC9521283          DOI: 10.4274/ejbh.galenos.2022.2022-5-8

Source DB:  PubMed          Journal:  Eur J Breast Health


  34 in total

Review 1.  Evolution of breast cancer treatments: current options and quality-of-life considerations.

Authors:  Lesley J Fallowfield
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

2.  Current state of quality of life and patient-reported outcomes research.

Authors:  Andrew Bottomley; Jaap C Reijneveld; Michael Koller; Henning Flechtner; Krzysztof A Tomaszewski; Eva Greimel
Journal:  Eur J Cancer       Date:  2019-09-24       Impact factor: 9.162

3.  Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis.

Authors:  Zoe Moon; Rona Moss-Morris; Myra S Hunter; Sam Norton; Lyndsay D Hughes
Journal:  Health Psychol       Date:  2019-07-25       Impact factor: 4.267

4.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Authors:  Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

5.  Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.

Authors:  Albert J Farias; Xianglin L Du
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

6.  Interpreting the significance of changes in health-related quality-of-life scores.

Authors:  D Osoba; G Rodrigues; J Myles; B Zee; J Pater
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Physical activity and body composition, body physique, and quality of life in premenopausal breast cancer patients during endocrine therapy--a feasibility study.

Authors:  Katarzyna Hojan; Marta Molińska-Glura; Piotr Milecki
Journal:  Acta Oncol       Date:  2012-11-29       Impact factor: 4.089

8.  Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.

Authors:  J G H van Nes; D B Y Fontein; E T M Hille; D W Voskuil; F E van Leeuwen; J C J M de Haes; H Putter; C Seynaeve; J W R Nortier; C J H van de Velde
Journal:  Breast Cancer Res Treat       Date:  2012-03-28       Impact factor: 4.872

9.  Factors associated to persistence with hormonal therapy in women with breast cancer.

Authors:  Cláudia Brito; Margareth Crisóstomo Portela; Mauricio Teixeira Leite de Vasconcellos
Journal:  Rev Saude Publica       Date:  2014-04       Impact factor: 2.106

Review 10.  Toward a comprehensive evidence map of overview of systematic review methods: paper 1-purpose, eligibility, search and data extraction.

Authors:  Carole Lunny; Sue E Brennan; Steve McDonald; Joanne E McKenzie
Journal:  Syst Rev       Date:  2017-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.